UBS Group’s HCW Biologics HCWB Stock Holding History

UBS Group’s Portfolio HCWB Stock Details HCWB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$5	Sell	1 -1,536	-100%	-$8.71K	﹤0.01%	10350
2026 Q1	$3.32K	Buy	1,537 +1,247	+430%	+$6.45K	﹤0.01%	9109
2025 Q4	$1.69K	Buy	+290	New	+$4.93K	﹤0.01%	9495
2025 Q3	–	Sell	-1,586	Closed	-$37.7K	–	10549
2025 Q2	$37.7K	Buy	+1,586	New	+$69.2K	﹤0.01%	8007
2024 Q4	–	Sell	-20	Closed	-$2.6K	–	10121
2024 Q3	$2.6K	Buy	20 +2	+11%	+$273	﹤0.01%	8402
2024 Q2	$2.77K	Buy	18 +15	+500%	+$4.43K	﹤0.01%	8303
2024 Q1	$1.06K	Hold	3	–	–	﹤0.01%	8243
2023 Q4	$778	Buy	3 +2	+200%	+$682	﹤0.01%	8516
2023 Q3	$403	Buy	+1	New	+$495	﹤0.01%	8520
2023 Q2	–	Hold	0	–	-$22	–	9193
2023 Q1	–	Sell	-2	Closed	-$866	–	9412
2022 Q4	$732	Buy	+2	New	+$1.03K	﹤0.01%	10087
2022 Q3	–	Sell	-9	Closed	-$5K	–	10572
2022 Q2	$5K	Buy	9 +2	+29%	+$1.12K	﹤0.01%	8878
2022 Q1	$5K	Buy	+7	New	+$3.73K	﹤0.01%	9126
2021 Q4	–	Sell	-156	Closed	-$119K	–	10434
2021 Q3	$119K	Buy	+156	New	+$164K	﹤0.01%	5704

Other funds holding HCWB

VFT

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

TRCT

Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return

CCM

Connective Capital Management Palo Alto, California $142M AUM 51.29% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

GSWM

Golden State Wealth Management Santa Ana, California $1.1B AUM 27.5% 1-Year Est. Return

CIAM

Caitong International Asset Management Hong Kong $729M AUM 1,176.98% 1-Year Est. Return

UBS Group's HCWB Position: Q2 2026 in Review

UBS Group reduced its HCW Biologics (HCWB) stake by 100% in Q2 2026, selling an estimated $8.71K and leaving 1 share worth $5. The position accounts for ﹤0.01% of the portfolio, ranked #10350.

UBS Group first reported a position in HCWB in Q3 2021 and has held it in 13 quarters since. The position peaked at $119K in Q3 2021. 7 funds tracked by Wall St. Rank hold HCWB as of Q2 2026.

UBS Group held 1 share of HCW Biologics worth $5 as of Q2 2026.
UBS Group sold 1,536 HCW Biologics shares in Q2 2026, an estimated $8.71K.
HCW Biologics made up ﹤0.01% of UBS Group's portfolio in Q2 2026, its #10350 holding.
UBS Group first reported a position in HCW Biologics in Q3 2021 and has held it in 13 quarters since.
UBS Group's HCW Biologics position peaked at $119K in Q3 2021.
7 funds tracked by Wall St. Rank held HCW Biologics as of Q2 2026.

Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.